2025-08151RuleWallet

Blood Clot Testing Device for Surgery Now Class II Approved

Published Date: 5/9/2025

Rule

Summary

The FDA is officially classifying a special blood test device used during surgery as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to new, helpful technology. The new rules took effect on May 9, 2025, and could save time and money for makers and users of these devices.

Analyzed Economic Effects

4 provisions identified: 3 benefits, 1 costs, 0 mixed.

Detailed study and testing requirements for manufacturers

Manufacturers must provide detailed design verification and validation, including precision studies, performance across the claimed measurement range, interferent testing, specimen stability, and multisite clinical studies. The rule requires multisite clinical testing at a minimum of three external sites and allows contrived specimens only to the extent of 10 to 20 percent of testing when needed.

Device moved to Class II (special controls)

The FDA officially classified the coagulation system for measuring whole blood viscoelastic properties in perioperative patients as Class II (special controls). This classification is effective May 9, 2025 and was applicable March 12, 2019. FDA says this reduces regulatory burdens and will enhance patients' access to the technology.

De Novo gives a predicate for future devices

Because FDA classified this device through the De Novo process, it can serve as a predicate for future devices of the same type, allowing other sponsors to use the less-burdensome 510(k) process instead of De Novo or premarket approval. FDA says this change can reduce regulatory burdens and save time and money for device makers.

Labeling limits on diagnostic claims

The device's labeling must say the device results are not intended to be the sole basis for a patient diagnosis. Unless specific clinical outcome studies are done and acceptable to FDA, labeling must also state the device has not been evaluated to guide blood product use or to guide medication use.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Rule Effective
5/9/2025
5/9/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register